Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 536,671) | 1,236,388) | 531,854) | 629,227) | 520,148) | |
| Invested capital2 | 3,344,477) | 2,990,610) | 2,459,204) | 1,524,413) | 1,516,250) | |
| Performance Ratio | ||||||
| ROIC3 | 16.05% | 41.34% | 21.63% | 41.28% | 34.30% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| Abbott Laboratories | 10.96% | 11.30% | — | — | — | |
| Elevance Health Inc. | 10.24% | 11.26% | — | — | — | |
| Intuitive Surgical Inc. | 22.01% | 37.63% | — | — | — | |
| Medtronic PLC | 7.02% | 5.59% | — | — | — | |
| UnitedHealth Group Inc. | 13.68% | 13.51% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 536,671 ÷ 3,344,477 = 16.05%
4 Click competitor name to see calculations.
The analysis of the Return on Invested Capital (ROIC) reveals a period of significant volatility between 2018 and 2022. While the company substantially expanded its invested capital base, the corresponding Net Operating Profit After Taxes (NOPAT) failed to maintain a consistent growth trajectory, leading to a marked decline in capital efficiency by the end of the period.
- Net Operating Profit After Taxes (NOPAT) Trends
- NOPAT exhibited extreme fluctuations over the five-year span. After a steady start in 2018 and 2019, a slight decline occurred in 2020, followed by a substantial surge in 2021, where it reached a peak of 1,236,388 thousand USD. However, this peak was short-lived, as 2022 saw a sharp contraction to 536,671 thousand USD, effectively returning profitability to 2018 levels.
- Invested Capital Expansion
- A consistent and aggressive upward trend is observed in invested capital. The capital base grew from 1,516,250 thousand USD in 2018 to 3,344,477 thousand USD in 2022. This represents a total increase of approximately 120%, indicating a significant commitment of resources into the business operations over the analyzed timeframe.
- Return on Invested Capital (ROIC) Analysis
- The ROIC demonstrates a pattern of instability, peaking at 41.28% in 2019 and 41.34% in 2021. The efficiency of the invested capital was severely impacted in 2022, with the ROIC dropping to its lowest point of 16.05%. This decline is the result of a compounding effect: a substantial reduction in NOPAT occurring simultaneously with a continued increase in the total invested capital base, suggesting that recent capital deployments have yielded lower marginal returns.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The Return on Invested Capital (ROIC) exhibits significant volatility from 2018 to 2022, characterized by cyclical peaks in 2019 and 2021 and a substantial decline by the end of the period. The ROIC reached a high of 41.34% in 2021 before falling to a five-year low of 16.05% in 2022, indicating a marked deterioration in the efficiency of capital deployment.
- Return on Invested Capital (ROIC)
- The overall return profile is inconsistent, showing a pattern of recovery and subsequent contraction. A sharp decline was observed in 2020 (21.63%), followed by a strong rebound in 2021, and another steep drop in 2022. This volatility suggests high sensitivity to operational shifts and external market conditions.
- Operating Profit Margin (OPM)
- Profitability margins fluctuated throughout the period, peaking at 33.28% in 2021. However, the margin contracted significantly in 2022 to 20.65%, representing the lowest margin in the five-year sequence and serving as a primary driver for the decline in the overall ROIC.
- Turnover of Capital (TO)
- Capital efficiency, as measured by the turnover ratio, demonstrated instability. A peak of 1.70 was achieved in 2019, but the ratio declined to 1.10 in 2020 and ended the period at 1.18 in 2022. The inability to sustain high capital turnover has limited the company's ability to generate revenue from its invested capital base.
- Effective Cash Tax Rate Impact (1 – CTR)
- The after-tax retention rate remained relatively stable, ranging between 84% and 88% from 2018 through 2021. A significant downward shift occurred in 2022, where the value dropped to 65.79%, which acted as an additional downward pressure on the net ROIC.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 536,671) | 1,236,388) | 531,854) | 629,227) | 520,148) | |
| Add: Cash operating taxes2 | 279,014) | 228,620) | 93,656) | 111,949) | 66,308) | |
| Net operating profit before taxes (NOPBT) | 815,685) | 1,465,008) | 625,510) | 741,176) | 586,456) | |
| Net revenues | 3,734,635) | 3,952,584) | 2,471,941) | 2,406,796) | 1,966,492) | |
| Add: Increase (decrease) in deferred revenues | 214,751) | 449,116) | 241,173) | 189,076) | 137,888) | |
| Adjusted net revenues | 3,949,386) | 4,401,700) | 2,713,114) | 2,595,872) | 2,104,380) | |
| Profitability Ratio | ||||||
| OPM3 | 20.65% | 33.28% | 23.06% | 28.55% | 27.87% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| Abbott Laboratories | 20.24% | 20.37% | — | — | — | |
| Elevance Health Inc. | 5.64% | 6.58% | — | — | — | |
| Intuitive Surgical Inc. | 26.19% | 33.56% | — | — | — | |
| Medtronic PLC | 19.15% | 16.48% | — | — | — | |
| UnitedHealth Group Inc. | 9.13% | 8.33% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted net revenues
= 100 × 815,685 ÷ 3,949,386 = 20.65%
4 Click competitor name to see calculations.
The operating performance from 2018 to 2022 is characterized by significant volatility in both absolute operating profit and efficiency ratios. While adjusted net revenues generally trended upward until 2021, the net operating profit before taxes (NOPBT) exhibited more erratic movements, leading to substantial fluctuations in the operating profit margin (OPM).
- Revenue and Profitability Trajectory
- Adjusted net revenues grew steadily from 2018 through 2020 before experiencing a sharp increase in 2021, reaching 4,401,700 thousand USD. This growth was followed by a contraction in 2022 to 3,949,386 thousand USD. NOPBT mirrored this trajectory but with greater amplitude, peaking in 2021 at 1,465,008 thousand USD before declining sharply to 815,685 thousand USD in 2022.
- Operating Profit Margin Fluctuations
- The operating profit margin displayed an inconsistent trend, starting at 27.87% in 2018 and peaking at 33.28% in 2021. A notable contraction occurred in 2020, where the margin fell to 23.06% despite a slight increase in revenues, indicating an increase in operating expenses relative to income during that fiscal year.
- Analysis of Margin Compression
- The period between 2021 and 2022 represents the most significant shift in operational efficiency. The OPM dropped from its five-year high of 33.28% to its five-year low of 20.65%. This decline is attributed to a disproportionate reduction in NOPBT relative to the decrease in adjusted net revenues, suggesting a significant compression of margins and an increase in the cost of operations during the final year of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net revenues | 3,734,635) | 3,952,584) | 2,471,941) | 2,406,796) | 1,966,492) | |
| Add: Increase (decrease) in deferred revenues | 214,751) | 449,116) | 241,173) | 189,076) | 137,888) | |
| Adjusted net revenues | 3,949,386) | 4,401,700) | 2,713,114) | 2,595,872) | 2,104,380) | |
| Invested capital1 | 3,344,477) | 2,990,610) | 2,459,204) | 1,524,413) | 1,516,250) | |
| Efficiency Ratio | ||||||
| TO2 | 1.18 | 1.47 | 1.10 | 1.70 | 1.39 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| Abbott Laboratories | 0.71 | 0.69 | — | — | — | |
| Elevance Health Inc. | 2.33 | 2.14 | — | — | — | |
| Intuitive Surgical Inc. | 1.16 | 1.27 | — | — | — | |
| Medtronic PLC | 0.46 | 0.42 | — | — | — | |
| UnitedHealth Group Inc. | 1.95 | 2.04 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Invested capital. See details »
2 2022 Calculation
TO = Adjusted net revenues ÷ Invested capital
= 3,949,386 ÷ 3,344,477 = 1.18
3 Click competitor name to see calculations.
The analysis of capital turnover between 2018 and 2022 reveals a period of significant volatility in asset efficiency, characterized by aggressive capital expansion and fluctuating revenue growth.
- Revenue Trajectory
- Adjusted net revenues exhibited a consistent upward trend from 2018 through 2021, increasing from US$ 2.10 billion to a peak of US$ 4.40 billion. However, this growth trend reversed in 2022, with revenues contracting to US$ 3.95 billion.
- Invested Capital Expansion
- Invested capital remained relatively stable between 2018 and 2019 at approximately US$ 1.52 billion. Starting in 2020, a phase of rapid capital expansion began, with the investment base increasing to US$ 2.46 billion in 2020 and continuing to grow steadily to reach US$ 3.34 billion by December 31, 2022.
- Turnover of Capital Efficiency
- The turnover ratio experienced significant fluctuations, peaking at 1.70 in 2019 as revenue grew while the capital base remained flat. A sharp decline to 1.10 was observed in 2020, driven by the sudden increase in invested capital. A recovery to 1.47 occurred in 2021, coinciding with a substantial surge in net revenues. However, the ratio declined again to 1.18 in 2022, resulting from the combination of decreasing revenues and a continuing increase in invested capital.
The observed data indicates that the expansion of the invested capital base has outpaced revenue growth in the latter stages of the period. This divergence led to a reduction in the efficiency of capital utilization by 2022 compared to the peak efficiency levels seen in 2019.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net operating profit after taxes (NOPAT)1 | 536,671) | 1,236,388) | 531,854) | 629,227) | 520,148) | |
| Add: Cash operating taxes2 | 279,014) | 228,620) | 93,656) | 111,949) | 66,308) | |
| Net operating profit before taxes (NOPBT) | 815,685) | 1,465,008) | 625,510) | 741,176) | 586,456) | |
| Tax Rate | ||||||
| CTR3 | 34.21% | 15.61% | 14.97% | 15.10% | 11.31% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| Abbott Laboratories | 23.97% | 20.05% | — | — | — | |
| Elevance Health Inc. | 22.01% | 20.22% | — | — | — | |
| Intuitive Surgical Inc. | 27.40% | 11.76% | — | — | — | |
| Medtronic PLC | 19.53% | 18.59% | — | — | — | |
| UnitedHealth Group Inc. | 23.25% | 20.32% | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 279,014 ÷ 815,685 = 34.21%
4 Click competitor name to see calculations.
Between the end of 2018 and 2022, the relationship between operating profitability and cash tax obligations exhibited significant volatility, culminating in a sharp increase in the effective cash tax rate during the final year of the period.
- Net Operating Profit Before Taxes (NOPBT)
- Operating profitability demonstrated a non-linear trajectory. After an initial increase from 586,456 thousand US$ in 2018 to 741,176 thousand US$ in 2019, NOPBT experienced a moderate decline in 2020. A substantial peak occurred in 2021, reaching 1,465,008 thousand US$, before contracting significantly to 815,685 thousand US$ by the end of 2022.
- Cash Operating Taxes
- Cash tax payments showed a general upward trend over the five-year horizon, despite a slight dip in 2020. Outlays rose from 66,308 thousand US$ in 2018 to 279,014 thousand US$ in 2022. Notably, the most aggressive growth in cash tax payments occurred between 2020 and 2022, where payments nearly tripled despite the fluctuating nature of the underlying operating profit.
- Effective Cash Tax Rate (CTR)
- The CTR remained relatively stable and low for the first four years of the analysis, fluctuating within a narrow band between 11.31% in 2018 and 15.61% in 2021. However, a dramatic shift occurred in 2022, with the CTR spiking to 34.21%. This increase is particularly noteworthy as it occurred during a year when NOPBT declined, suggesting that the rise in the tax rate was not driven by increased operating profitability, but rather by other fiscal factors or a reduction in available tax deferrals.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?